BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Brentwood Medical Obtains FDA Approval for New Medical Device


12/11/2012 8:48:40 AM

A medical company with a pilot plant in Brentwood recently became the first company worldwide to obtain U.S. Food and Drug Administration approval for surgically treating uterine fibroids. Halt Medical spent nearly a decade testing and developing the medical device, called Acessa, before receiving an FDA clearance last month. The human clinical trial for Acessa involved 137 patients of various racial backgrounds at 11 different sites in the United States, Mexico and Guatemala, according to Halt CEO Jeff Cohen. "It is big news. We are still celebrating," said Cohen last week. "We are thrilled to be in a position to fundamentally improve women's health care." According to Cohen, Acessa uses radio-frequency energy to heat the tissue and destroy the uterine fibroids, which are later absorbed by the surrounding tissue. This technology allows doctors to use a minimally invasive surgery rather than do a hysterectomy, which was usually used to remove the fibroids. Dr. Don Galen, a San Ramon-based gynecologist, said among the advantages of Acessa is that it is an outpatient procedure, it involves less discomfort for patients because there is no large incision, and it doesn't require removing the majority of the uterine tissue. "It would allow us to actually treat virtually all of the fibroids in the uterus in any location in the uterus because of the high-resolution ultrasound that was used as part of the procedure," Galen said. In the United States, 7.5 million women suffer from symptomatic uterine fibroids and only 300,000 women have a procedure done to cure it, Cohen said. "Most women would rather suffer with it than have a hysterectomy," he said. Among the common symptoms of uterine fibroids is excessive bleeding, painful sexual intercourse, incontinence, infertility and pain. Through the Acessa trial, women saw a significant reduction in symptoms during the first three to six months, and 98 percent of them would recommend it to their friends. "Often, these women only wear black, don't leave their houses or don't have intercourse," Cohen said. "We significantly reduced their bleeding. It changes your life. You can become a prisoner of it (fibroids)."

Read at Mercury News

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES